Novel therapy for IBD

- Rectal therapy with compound X – an investment opportunity

Biotech and Health Care

Key selling points
We have invented a novel therapeutic principle for treatment of inflammatory bowel disease and the therapy is especially well suited for the treatment of ulcerative colitis. The current state-of-the-art therapy for IBD targets the immune system and involves the use of 5-aminosalicylates, steroids, thiopurines and biological therapies such as e.g. anti-tumor necrosis factor alpha antibodies.

The unique properties of the therapy are:
• Based on the repurposing of a known substance – compound X
• Targeting the epithelium rather than the immune system
• Anti-tumorigenic effect in the colon

Business Opportunity/commercial perspectives
We seek investors to enter the pre-seed / seed phase following the planned human pilot study.
With rectal compound X therapy our first priority is ulcerative colitis with limited extension with an estimated worldwide annual market of 1.7 billion USD. It is envisioned that rectal compound X therapy can reach an initial 2% of the market for treatment of ulcerative colitis, rising to 20% within five years of marketing.

Technology description
Compound X is instilled rectally in a volume of 100-200 ml of phosphate buffered saline. The volume may be increased in order to increase the mucosal area covered. Compound X is administered daily during active disease by the patients themselves at home. The rectal administration is already used for the drugs most frequently used in IBD (steroids and 5-aminosalicylates) and is well tolerated by the patients.
Compound X may also be used in combination with existing IBD therapies.

Development phase
Based on a solid basis of experimental evidence from experiments in the murine azoxymethane (AOM) + dextran sulphate sodium (DSS) model for inflammation and inflammation induced colorectal cancer, we are currently taking the project into a human pilot study.

The inventors
Prof. DMSc, MD, Jørgen Olsen
Ph.D. MSc, Mohammad Yassin
DMSc, MD, Anders Elm Pedersen

Contact information
Peter Stein Nielsen
Commercial Officer
peter.nielsen@adm.ku.dk
+45 2164 7447